Chardan Capital Maintains Buy on Coya Therapeutics, Raises Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae maintains a Buy rating on Coya Therapeutics (NASDAQ:COYA) and raises the price target from $9 to $11.
June 08, 2023 | 9:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Coya Therapeutics and raises the price target from $9 to $11.
Chardan Capital's Buy rating and increased price target for Coya Therapeutics indicate a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100